M Martinez et al. Hepatology 2021; 74: 2047-2057. Recurrence of Primary Sclerosing Cholangitis After Liver Transplant in Children: An International Observational Study
In this retrospective study, the authors examined recurrent PSC (rPSC) in children who had undergone liver transplantation (LT) with 3 yrs of median followup. Key findings:
- rPSC occurred in 36 children, representing 10% and 27% of the subjects at 2 years and 5 years following LT, respectively
- Subjects with rPSC were younger at LT (12.9 vs. 16.2 years), had faster progression from PSC diagnosis to LT (2.5 vs. 4.1 years), and had higher alanine aminotransferase (112 vs. 66 IU/L) at LT (all P < 0.01)
- After LT, rPSC subjects had more episodes of biopsy-proved acute rejection (mean 3 vs. 1; P < 0.001), and higher prevalence of steroid-refractory rejection (41% vs. 20%; P = 0.04)
My take: rPSC, not surprisingly, was associated with a more agressive, immunoreactive phenotype prior to LT characterized by younger age, faster progression to end-stage liver disease, higher prevalence of IBD and more frequent/difficult allograft rejection
Related blog posts:
- PSC -Aspen 2021 Webinar This lecture highlights studies show lack of efficacy with vancomycin, ursodeoxycholic acid and vedolizumab. Also, there is potential utility of MMP-7 for distinguishing between PSC and AIH
- Easy Advice for Pediatric Hepatologists for PSC Surveillance -for hepatobiliary cancer (usually ‘begin at age 20 yrs’)
- Ursodeoxycholic Acid for Pediatric PSC
- Active Colitis More Likely in Children with PSC-IBD
- Big Study of PSC in Children
- PSC -Natural History Study (pediatric)
- Primary Sclerosing Cholangitis (PSC) –Natural History Study
- Why does PSC increase the risk of colorectal cancer in UC?
- Should We Care About Subclinical Primary Sclerosing Cholangitis with Inflammatory Bowel Disease?